GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (STU:2QA) » Definitions » Price-to-Operating-Cash-Flow

Altamira Therapeutics (STU:2QA) Price-to-Operating-Cash-Flow : (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Altamira Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-21), Altamira Therapeutics's share price is €4.708. Altamira Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.36. Hence, Altamira Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Altamira Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

STU:2QA's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.93
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Altamira Therapeutics's Cash Flow from Operations per share for the six months ended in Dec. 2023 was €-0.80. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.36.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 57.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 60.70% per year.

During the past 13 years, Altamira Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 75.50% per year. The lowest was 45.00% per year. And the median was 58.60% per year.


Altamira Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Altamira Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Price-to-Operating-Cash-Flow Chart

Altamira Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Altamira Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Altamira Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Altamira Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altamira Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Price-to-Operating-Cash-Flow falls into.



Altamira Therapeutics Price-to-Operating-Cash-Flow Calculation

Altamira Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=4.708/-2.359
=

Altamira Therapeutics's Share Price of today is €4.708.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Altamira Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics (STU:2QA) Business Description

Traded in Other Exchanges
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

Altamira Therapeutics (STU:2QA) Headlines

No Headlines